Attached is the summons to the Extraordinary General
Meeting in CellCura ASA on 10 January 2012 at 10:00 am in
Munkedamsveien 45 A, 5th floor, Oslo, Norway.
One the agenda is
-
Proposal for a subsequent (repair) share offering *
-
Adoption of an agreement with Dag Dvergsten AS
-
Proposal regarding authorisation to the Board of
Directors to conduct share capital increases
* CellCura ASA has carried out a successful private
placement of 6,448,222 shares directed towards large
existing shareholders and new institutional investors after
the close of the Oslo Stock Exchange on 16 December 2011.
The private placement was done at a share price of NOK 1.20
per share. The Board of Directors therefore proposes that
the Extraordinary General Meeting resolves a subsequent
(repair) share offering towards the shareholders in
CellCura ASA as at 16 December 2011 who were not invited to
participate in the private placement.
Oslo, 19 December 2011
CellCura ASA
Lars Bredahl
Chief Executive Officer
Phone: +47 90 82 40 75
CellCura ASA is dedicated to the development and sales of
cell technologies for use in assisted reproductive
technology (ART) and stem cell research worldwide,
representing improved safety and efficiency compared to
traditional technology. CellCura ASA is listed on the Oslo
Axess market at the Oslo Stock Exchange (ticker: CELL).
www.cellcura.com
This information is subject of the disclosure requirements
acc. to §5-12 vphl (Norwegian Securities Trading Act)
Recommend:
